Kindred Biosciences, Inc.KINNASDAQ

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

prnewswire.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds CVA, SWN, RIVE, and KIN Shareholders About Its Ongoing Investigations

NEW YORK, July 21, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP1500 Broadway, 16th Floor New York, NY 10036 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Covanta Holding Corporation (NYSE: CVA) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Covanta Holding Corporation (NYSE: CVA) in connection with the proposed acquisition of the company by EQT Infrastructure.

prnewswire.com

Moore Kuehn Encourages KIN, SVOK, ROCR, and DCRC Investors to Contact Law Firm

NEW YORK, June 22, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: Kindred Biosciences, Inc. (NASDAQ: KIN) Kindred Bioscience has agreed to merge with Elanco Health.

businesswire.com

KINDRED BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kindred Biosciences, Inc. - KIN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kindred Biosciences, Inc. (NasdaqGS: KIN) to Elanco Animal Health Incorporated (NYSE: ELAN). Under the terms of the proposed transaction, shareholders of Kindred will receive only $9.25 for each share of Kindred that they own. KSF is seeking to determine whether this consideration and the process that led to i

prnewswire.com

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kindred Biosciences, Inc. - KIN

NEW YORK, June 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Kindred Biosciences, Inc. ("KIN" or the "Company") (KIN) relating to its proposed acquisition by Elanco Animal Health, Inc. KIN shareholders will receive $9.25 in cash per share they own. The investigation focuses on whether Kindred Biosciences, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

fool.com

Why Kindred Biosciences Stock Skyrocketed Today

The pet therapeutics pioneer is being scooped up by a global animal health leader.

invezz.com

Kindred Biosciences to merge with Elanco Animal Health

Elanco Animal Health Inc (NYSE: ELAN) said on Wednesday it will acquire Kindred Biosciences Inc (NASDAQ: KIN) for roughly $440 million (£312 million) to expand its footprint in the pet health industry. The acquisition will bring three potential dermatology blockbusters, which are currently in the development phase, under Elanco's umbrella.

benzinga.com

Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest biopharma movers on Wednesday. Kindred Flies On Buyout: Kindred announced an agreement to be bought by Elanco Animal Health Incorporated (NYSE: ELAN) for $9.25 per share, or approximately $440 million.

businesswire.com

Kindred Biosciences Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kindred Biosciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – KIN

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kindred Biosciences, Inc. (NASDAQ: KIN) to Elanco Animal Health Incorporated for $9.25 per share is fair to Kindred Biosciences shareholders. Halper Sadeh encourages Kindred Biosciences shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The i

pulse2.com

KIN Stock Price Increases Over 45% Pre-Market: Why It Happened

The stock price of Kindred Biosciences Inc (NASDAQ: KIN) increased by over 45% pre-market. This is why it happened.

marketwatch.com

Elanco Animal Health to acquire Kindred Biosciences for about $440 million; Kindred shares soar 45% premarket

Elanco Animal Health Inc. said Wednesday it has entered an agreement to acquire Kindred Biosciences Inc. for about $440 million, adding three potential dermatology blockbusters to its pipeline. Under the terms of the deal, Elanco will pay $9.l254 a share for each Kindred share owned, equal to a 52% premium based on the 30-day average closing price.

prnewswire.com

Elanco Announces Agreement to Acquire Kindred Biosciences

GREENFIELD, Ind. and SAN FRANCISCO, June 16, 2021 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) and Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN) today announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets.

zacks.com

Kindred Bio (KIN) Soars 16%: Is Further Upside Left in the Stock?

Kindred Bio (KIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

prnewswire.com

Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XI

SAN FRANCISCO, May 25, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2021 Virtual Jaws & Paws Conference on June 2 and the LD Micro Invitational XI on June 8. Dr. Richard Chin, Chief Executive Officer, will be available for one-on-one meetings.

seekingalpha.com

Kindred Biosciences, Inc. (KIN) CEO Dr. Richard Chin on Q1 2021 Results - Earnings Call Transcript

prnewswire.com

Kindred Biosciences Announces First Quarter 2021 Financial Results

SAN FRANCISCO, May 11, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2021 and provided updates on its programs. For the first quarter 2021, KindredBio reported net revenues of $2.4 million and a net loss of $9.7 million, or $0.24 per share.

prnewswire.com

Kindred Biosciences to Announce First Quarter 2021 Financial Results

SAN FRANCISCO, May 3, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first quarter 2021 financial results on May 11, 2021, after the market close. The Company will host a conference call at 4:30 p.m.

Week 18 MDA Breakout Stocks - May 2021: Short-Term Picks To Give You An Edge

seekingalpha.com

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance